semaglutide and cancer A growing body of research suggests popular weight-loss drugs, like Ozempic Wegovy, may also help treat or prevent certain cancers., Researchers say there are still many open questions, as the How Semaglutide May Reduce The

The Appetite Suppression Problem When appetite is significantly suppressed, total food intake drops, often dramatically

At low, carefully controlled doses, it is commonly used to support mental focus, memory, and overall brain health, as well as general energy levels

## Head-to-Head Comparison: AOD-9604 vs Semaglutide ### Clinical Evidence for Weight Loss This is where the comparison becomes decisive

IGF-1 DES has a 20-30 minute half-life but is about 10x more potent, making it best for localized, site-specific applications where it's injected directly into target muscles before training

What's New: July 2026 Update TRIUMPH-4 confirmed as final: 28.7% weight loss at 68 weeks in 445 participants peer-reviewed Phase 3 data, December 2025 TRIUMPH-1 CONFIRMED (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients the pivotal general obesity trial met all primary and key secondary endpoints TRIUMPH-1 extension: In a prespecified 104-week extension, patients reached 30.3% average weight loss weight loss does not plateau at 80 weeks TRANSCEND-T2D-1 CONFIRMED (topline March 2026, published June 2026): First dedicated Phase 3 diabetes trial -2.0% HbA1c and 16.8% weight loss in 537 type 2 diabetes patients, separate from the TRIUMPH obesity program OSA data confirmed (ADA June 6, 2026): TRIUMPH-1's nested sleep apnea substudy showed 60.6% AHI reduction from a severe-OSA baseline of 58.6 events/hour TRIUMPH-2 (obesity + diabetes) and TRIUMPH-3 (obesity + cardiovascular disease) results expected later in 2026 Introduction Retatrutide's clinical journey tells a story of escalating and now confirmed efficacy